Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02072993 · ClinicalTrials.gov registry record · Phase 1
A First Time in Man Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD1979 in Healthy Males
A Phase 1 study, sponsored by AstraZeneca.
- Terminated
- Registry status
- Phase 1
- Development phase
- 116
- Enrollment target
NCT02072993 is a Phase 1 study that was terminated before completion, run by AstraZeneca. The registered enrollment target is 116 participants.
The verdict
NCT02072993, a Phase 1 study, was terminated before completion, sponsored by AstraZeneca.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 116 participants
- Enrollment target
Study Summary
This is a first time in human study to assess the safety and tolerability of AZD1979 following oral administration of single ascending doses in healthy male volunteers. Pharmacokinetics (what the body does to the drug) parameters will also be assessed as secondary objectives.
Interventions
- DRUG Placebo to match
- DRUG AZD1979
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 116 participants |
| Start Date | 2014-03 |
| Est. Completion | 2014-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02072993
The ClinicalTrials.gov registry entry for NCT02072993 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 116 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo to match is the first listed.
NCT02072993 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02072993 about?
NCT02072993 is a clinical study titled "A First Time in Man Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD1979 in Healthy Males". This is a first time in human study to assess the safety and tolerability of AZD1979 following oral administration of single ascending doses in healthy male volunteers. Pharmacokinetics (what the body does to the drug) parameters will also be assessed as secondary objectives.
What is the current status of trial NCT02072993?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 116 participants. The study started on 2014-03. Estimated completion is 2014-07.
What interventions are being tested in trial NCT02072993?
The interventions under investigation include: Placebo to match (DRUG), AZD1979 (DRUG).
Who is sponsoring clinical trial NCT02072993?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.